Alphyn Biologics Secures $25M for Clinical Trials in Dermatology

Alphyn Biologics secures $25 million in Series B financing to advance Zabalafin Hydrogel for atopic dermatitis and molluscum contagiosum virus.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here